Cefoxitin

Cefoxitin

Cefoxitin
Systematic (IUPAC) name
(6S,7R)-4-(carbamoyloxymethyl)-7-methoxy-
8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade names Mefoxin
AHFS/Drugs.com
MedlinePlus
Pregnancy cat.
  • B
Legal status
?
Routes IV
Pharmacokinetic data
Metabolism minimal
Half-life 41-59 min
Excretion 85% urine
Identifiers
CAS number  YesY
ATC code J01
PubChem
DrugBank
ChemSpider  YesY
UNII  YesY
KEGG  N
ChEBI  N
ChEMBL  N
Chemical data
Formula C16H17N3O7S2 
Mol. mass 427.454 g/mol
 N   

Cefoxitin is a cephamycin antibiotic developed by Merck & Co., Inc., often grouped with the second−generation cephalosporins. It is sold under the brand name Mefoxin.

Microbiology

Cefoxitin acts by interfering with cell wall synthesis. Its activity spectrum includes a broad range of gram-negative and gram-positive bacteria including anaerobes. It is inactive in vitro to most strains of Pseudomonas aeruginosa and many strains of Enterobacter cloacae. Staphylococci resistant to methicillin/oxacillin should be considered resistant to cefoxitin. [1]

Cefoxitin is considered to be a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem).[2]

Spectrum of Bacterial Susceptibility

Cefoxitin has a broad spectrum of activity and has been used in the treatment of skin, bone, respiratory and urinary tract infections. Susceptible bacteria include some Staphylococci, Enterococci, Streptococci, and others. The following represents MIC susceptibility data for a few medically significant microorganisms.

  • Escherichia coli: 0.2 μg/ml - 64 μg/ml
  • Haemophilus influenzae: 0.5 μg/ml - 12.5 μg/ml
  • Streptococcus pneumoniae: 0.2 μg/ml - 1 μg/ml

[3]

References

  1. ^ Mefoxin Official FDA information at Drugs.com
  2. ^ Phillips I, Shannon K (1993). "Importance of beta-lactamase induction". Eur J Clin Microbiol Infect Dis. 12 Suppl 1: S19–26.  
  3. ^ http://www.toku-e.com/Assets/MIC/Cefoxitin.pdf